Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Promotional Reviews Decline, But Says It's Only Part Of Job

Executive Summary

US agency's Office of Prescription Drug Promotion may complete 37% fewer drug promotional material reviews in FY 2017 than previous year.

Advertisement

Related Content

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
Off-Label Promotion Decisions Likely Made Case-by-Case, US FDA Official Says
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS121339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel